(NASDAQ: LENZ) Lenz Therapeutics's forecast annual revenue growth rate of 136% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.47%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.4%.
Lenz Therapeutics's revenue in 2026 is $17,500,000.On average, 9 Wall Street analysts forecast LENZ's revenue for 2026 to be $1,666,535,039, with the lowest LENZ revenue forecast at $1,252,631,329, and the highest LENZ revenue forecast at $1,990,824,278. On average, 8 Wall Street analysts forecast LENZ's revenue for 2027 to be $4,242,919,796, with the lowest LENZ revenue forecast at $3,670,626,263, and the highest LENZ revenue forecast at $4,599,625,443.
In 2028, LENZ is forecast to generate $7,285,869,282 in revenue, with the lowest revenue forecast at $6,099,040,757 and the highest revenue forecast at $9,692,067,898.